Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Drug Development Series: Review

  • Drug Development Series: Review
    Disrupting insulin-like growth factor signaling as a potential cancer therapy
    Deepali Sachdev and Douglas Yee
    Mol Cancer Ther January 1 2007 6 (1) 1-12; DOI:10.1158/1535-7163.MCT-06-0080

Reviews

  • Reviews
    About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work
    Zuben E. Sauna and Suresh V. Ambudkar
    Mol Cancer Ther January 1 2007 6 (1) 13-23; DOI:10.1158/1535-7163.MCT-06-0155

  • Reviews
    Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy
    Hong Chang and Aaron D. Schimmer
    Mol Cancer Ther January 1 2007 6 (1) 24-30; DOI:10.1158/1535-7163.MCT-06-0443

Research Articles: Therapeutics, Targets, and Development

  • Research Articles: Therapeutics, Targets, and Development
    Effect of population and gender on chemotherapeutic agent–induced cytotoxicity
    Rong Stephanie Huang, Emily O. Kistner, Wasim K. Bleibel, Sunita J. Shukla and M. Eileen Dolan
    Mol Cancer Ther January 1 2007 6 (1) 31-36; DOI:10.1158/1535-7163.MCT-06-0591

  • Research Articles: Therapeutics, Targets, and Development
    Nuclear factor-κB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101
    Jianming Duan, Jay Friedman, Liesl Nottingham, Zhong Chen, Gulshan Ara and Carter Van Waes
    Mol Cancer Ther January 1 2007 6 (1) 37-50; DOI:10.1158/1535-7163.MCT-05-0285

  • Research Articles: Therapeutics, Targets, and Development
    Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation
    Deborah L. Marrocco, Wayne D. Tilley, Tina Bianco-Miotto, Andreas Evdokiou, Howard I. Scher, Richard A. Rifkind, Paul A. Marks, Victoria M. Richon and Lisa M. Butler
    Mol Cancer Ther January 1 2007 6 (1) 51-60; DOI:10.1158/1535-7163.MCT-06-0144

  • Research Articles: Therapeutics, Targets, and Development
    Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib
    Jiabin An and Matthew B. Rettig
    Mol Cancer Ther January 1 2007 6 (1) 61-69; DOI:10.1158/1535-7163.MCT-06-0255

  • Research Articles: Therapeutics, Targets, and Development
    Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma
    Yukihiko Kato, Brenda C. Salumbides, Xiao-Fei Wang, David Z. Qian, Simon Williams, Yongfeng Wei, Tolib B. Sanni, Peter Atadja and Roberto Pili
    Mol Cancer Ther January 1 2007 6 (1) 70-81; DOI:10.1158/1535-7163.MCT-06-0125

  • Research Articles: Therapeutics, Targets, and Development
    Combination treatment with arsenic trioxide and phytosphingosine enhances apoptotic cell death in arsenic trioxide–resistant cancer cells
    Moon-Taek Park, Young-Hee Kang, In-Chul Park, Chun-Ho Kim, Yun-Sil Lee, Hee Yong Chung and Su-Jae Lee
    Mol Cancer Ther January 1 2007 6 (1) 82-92; DOI:10.1158/1535-7163.MCT-06-0349

  • Research Articles: Therapeutics, Targets, and Development
    Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling
    Peter Mullen, David A. Cameron, Max Hasmann, John F. Smyth and Simon P. Langdon
    Mol Cancer Ther January 1 2007 6 (1) 93-100; DOI:10.1158/1535-7163.MCT-06-0401

  • Research Articles: Therapeutics, Targets, and Development
    Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts
    Satoshi Anai, Steve Goodison, Kathleen Shiverick, Yoshihiko Hirao, Bob D. Brown and Charles J. Rosser
    Mol Cancer Ther January 1 2007 6 (1) 101-111; DOI:10.1158/1535-7163.MCT-06-0367

  • Research Articles: Therapeutics, Targets, and Development
    Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, Atiprimod
    Sweeta R. Choudhari, Muhammad A. Khan, Genesis Harris, Donald Picker, Gary S. Jacob, Timothy Block and Kunwar Shailubhai
    Mol Cancer Ther January 1 2007 6 (1) 112-121; DOI:10.1158/1535-7163.MCT-06-0561

  • Research Articles: Therapeutics, Targets, and Development
    MRP8/ABCC11 directly confers resistance to 5-fluorouracil
    Tetsuya Oguri, Yuji Bessho, Hiroyuki Achiwa, Hiroaki Ozasa, Ken Maeno, Hiroyoshi Maeda, Shigeki Sato and Ryuzo Ueda
    Mol Cancer Ther January 1 2007 6 (1) 122-127; DOI:10.1158/1535-7163.MCT-06-0529

  • Research Articles: Therapeutics, Targets, and Development
    The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells
    Wendy L. Allen, Estelle G. McLean, John Boyer, Andrea McCulla, Peter M. Wilson, Vicky Coyle, Daniel B. Longley, Robert A. Casero Jr. and Patrick G. Johnston
    Mol Cancer Ther January 1 2007 6 (1) 128-137; DOI:10.1158/1535-7163.MCT-06-0303

  • Research Articles: Therapeutics, Targets, and Development
    Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma
    Hung Huynh, Khee Chee Soo, Pierce K.H. Chow and Evelyn Tran
    Mol Cancer Ther January 1 2007 6 (1) 138-146; DOI:10.1158/1535-7163.MCT-06-0436

  • Research Articles: Therapeutics, Targets, and Development
    Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint
    Shi-Ken Sha, Takuji Sato, Hidetaka Kobayashi, Machiyo Ishigaki, Sayaka Yamamoto, Hitoshi Sato, Asako Takada, Sigetosi Nakajyo, Yasuo Mochizuki, Jonathan M. Friedman, Fong-Chi Cheng, Takashi Okura, Ryohei Kimura, Donald W. Kufe, Daniel D. VonHoff and Takumi Kawabe
    Mol Cancer Ther January 1 2007 6 (1) 147-153; DOI:10.1158/1535-7163.MCT-06-0371

  • Research Articles: Therapeutics, Targets, and Development
    Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes
    Melinda S. Yates, Masafumi Tauchi, Fumiki Katsuoka, Kathleen C. Flanders, Karen T. Liby, Tadashi Honda, Gordon W. Gribble, Delinda A. Johnson, Jeffrey A. Johnson, Neal C. Burton, Tomás R. Guilarte, Masayuki Yamamoto, Michael B. Sporn and Thomas W. Kensler
    Mol Cancer Ther January 1 2007 6 (1) 154-162; DOI:10.1158/1535-7163.MCT-06-0516

  • Research Articles: Therapeutics, Targets, and Development
    Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase
    Sheldon Holder, Marina Zemskova, Chao Zhang, Maryam Tabrizizad, Ryan Bremer, Jonathan W. Neidigh and Michael B. Lilly
    Mol Cancer Ther January 1 2007 6 (1) 163-172; DOI:10.1158/1535-7163.MCT-06-0397

  • Research Articles: Therapeutics, Targets, and Development
    HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor
    Natalya M. Kogan, Michael Schlesinger, Esther Priel, Ruth Rabinowitz, Eduard Berenshtein, Mordechai Chevion and Raphael Mechoulam
    Mol Cancer Ther January 1 2007 6 (1) 173-183; DOI:10.1158/1535-7163.MCT-06-0039

  • Research Articles: Therapeutics, Targets, and Development
    Eupalmerin acetate, a novel anticancer agent from Caribbean gorgonian octocorals, induces apoptosis in malignant glioma cells via the c-Jun NH2-terminal kinase pathway
    Arifumi Iwamaru, Eiji Iwado, Seiji Kondo, Robert A. Newman, Burnilda Vera, Abimael D. Rodríguez and Yasuko Kondo
    Mol Cancer Ther January 1 2007 6 (1) 184-192; DOI:10.1158/1535-7163.MCT-06-0422

  • Research Articles: Therapeutics, Targets, and Development
    D-501036, a novel selenophene-based triheterocycle derivative, exhibits potent in vitro and in vivo antitumoral activity which involves DNA damage and ataxia telangiectasia–mutated nuclear protein kinase activation
    Shin-Hun Juang, Chia-Chi Lung, Pi-Chen Hsu, Kuo-Shun Hsu, Yu-Chen Li, Pao-Chiung Hong, Her-Shyong Shiah, Ching-Chuan Kuo, Ching-Wei Huang, Yu-Chin Wang, Leeyuan Huang, Tom S. Chen, Shyh-Fong Chen, Kuo-Chu Fu, Cheng-Li Hsu, Meng-Ju Lin, Ching-jer Chang, Curtis L. Ashendel, Thomas C.K. Chan, Kai-Ming Chou and Jang-Yang Chang
    Mol Cancer Ther January 1 2007 6 (1) 193-202; DOI:10.1158/1535-7163.MCT-06-0482

  • Research Articles: Therapeutics, Targets, and Development
    Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma
    Tamantha K. Stutchbury, Fares Al-ejeh, Gillian E. Stillfried, David R. Croucher, John Andrews, David Irving, Matthew Links and Marie Ranson
    Mol Cancer Ther January 1 2007 6 (1) 203-212; DOI:10.1158/1535-7163.MCT-06-0264

  • Research Articles: Therapeutics, Targets, and Development
    XR5944: A potent inhibitor of estrogen receptors
    Chandanamali Punchihewa, Adrian De Alba, Neil Sidell and Danzhou Yang
    Mol Cancer Ther January 1 2007 6 (1) 213-219; DOI:10.1158/1535-7163.MCT-06-0392

  • Research Articles: Therapeutics, Targets, and Development
    Chrysin inhibits expression of hypoxia-inducible factor-1α through reducing hypoxia-inducible factor-1α stability and inhibiting its protein synthesis
    Beibei Fu, Jing Xue, Zhaodong Li, Xianglin Shi, Bing-Hua Jiang and Jing Fang
    Mol Cancer Ther January 1 2007 6 (1) 220-226; DOI:10.1158/1535-7163.MCT-06-0526

  • Research Articles: Therapeutics, Targets, and Development
    Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy
    Hiroaki Itamochi, Junzo Kigawa, Yasunobu Kanamori, Tetsuro Oishi, Chandra Bartholomeusz, Rita Nahta, Francisco J. Esteva, Nour Sneige, Naoki Terakawa and Naoto T. Ueno
    Mol Cancer Ther January 1 2007 6 (1) 227-235; DOI:10.1158/1535-7163.MCT-05-0499

  • Research Articles: Therapeutics, Targets, and Development
    Heat-inducible in vivo gene therapy of colon carcinoma by human mdr1 promoter–regulated tumor necrosis factor-α expression
    Wolfgang Walther, Franziska Arlt, Iduna Fichtner, Jutta Aumann, Ulrike Stein and Peter M. Schlag
    Mol Cancer Ther January 1 2007 6 (1) 236-243; DOI:10.1158/1535-7163.MCT-06-0070

  • Research Articles: Therapeutics, Targets, and Development
    Pulmonary adenocarcinoma–targeted gene therapy by a cancer- and tissue-specific promoter system
    Takuya Fukazawa, Yutaka Maeda, Mary L. Durbin, Toru Nakai, Junji Matsuoka, Hirotoshi Tanaka, Yoshio Naomoto and Noriaki Tanaka
    Mol Cancer Ther January 1 2007 6 (1) 244-252; DOI:10.1158/1535-7163.MCT-06-0408

  • Research Articles: Therapeutics, Targets, and Development
    Endothelin signaling in osteoblasts: global genome view and implication of the calcineurin/NFAT pathway
    Charles Van Sant, Gang Wang, Mark G. Anderson, Oscar J. Trask, Rick Lesniewski and Dimitri Semizarov
    Mol Cancer Ther January 1 2007 6 (1) 253-261; DOI:10.1158/1535-7163.MCT-06-0574

  • Research Articles: Therapeutics, Targets, and Development
    The JAMM motif of human deubiquitinase Poh1 is essential for cell viability
    Melissa Gallery, Jonathan L. Blank, Yinghui Lin, Juan A. Gutierrez, Jacqueline C. Pulido, David Rappoli, Sunita Badola, Mark Rolfe and Kyle J. MacBeth
    Mol Cancer Ther January 1 2007 6 (1) 262-268; DOI:10.1158/1535-7163.MCT-06-0542

  • Research Articles: Therapeutics, Targets, and Development
    Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells
    Aparna V. Sarthy, Susan E. Morgan-Lappe, Dorothy Zakula, Lawrence Vernetti, Mark Schurdak, Jeremy C.L. Packer, Mark G. Anderson, Senji Shirasawa, Takehiko Sasazuki and Stephen W. Fesik
    Mol Cancer Ther January 1 2007 6 (1) 269-276; DOI:10.1158/1535-7163.MCT-06-0560

  • Research Articles: Therapeutics, Targets, and Development
    Molecular correlates of gefitinib responsiveness in human bladder cancer cells
    Marissa Shrader, Maria Simona Pino, Gordon Brown, Peter Black, Liana Adam, Menahse Bar-Eli, Colin P.N. Dinney and David J. McConkey
    Mol Cancer Ther January 1 2007 6 (1) 277-285; DOI:10.1158/1535-7163.MCT-06-0513

  • Research Articles: Therapeutics, Targets, and Development
    Novel cell death pathways induced by N-(4-hydroxyphenyl)retinamide: therapeutic implications
    Roberta Venè, Giuseppe Arena, Alessandro Poggi, Cristina D'Arrigo, Michele Mormino, Douglas M. Noonan, Adriana Albini and Francesca Tosetti
    Mol Cancer Ther January 1 2007 6 (1) 286-298; DOI:10.1158/1535-7163.MCT-06-0346

  • Research Articles: Therapeutics, Targets, and Development
    Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells
    Masayuki Kamada, Alan So, Mototsugu Muramaki, Palma Rocchi, Eliana Beraldi and Martin Gleave
    Mol Cancer Ther January 1 2007 6 (1) 299-308; DOI:10.1158/1535-7163.MCT-06-0417

  • Research Articles: Therapeutics, Targets, and Development
    Synergism between vitamin D and secreted protein acidic and rich in cysteine–induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy
    Farnaz Taghizadeh, Michelle J. Tang and Isabella T. Tai
    Mol Cancer Ther January 1 2007 6 (1) 309-317; DOI:10.1158/1535-7163.MCT-06-0517

  • Research Articles: Therapeutics, Targets, and Development
    Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly
    Martine Cazales, Rose Boutros, Marie-Christine Brezak, Sophie Chaumeron, Grégoire Prevost and Bernard Ducommun
    Mol Cancer Ther January 1 2007 6 (1) 318-325; DOI:10.1158/1535-7163.MCT-06-0299

  • Research Articles: Therapeutics, Targets, and Development
    The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized low-density lipoprotein
    Stephanie Brändlein, Nicole Rauschert, Leo Rasche, Angela Dreykluft, Frank Hensel, Ernst Conzelmann, Hans-Konrad Müller-Hermelink and H. Peter Vollmers
    Mol Cancer Ther January 1 2007 6 (1) 326-333; DOI:10.1158/1535-7163.MCT-06-0399

  • Research Articles: Therapeutics, Targets, and Development
    Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells
    Devyani Chaudhuri, Sandra Orsulic and Badithe T. Ashok
    Mol Cancer Ther January 1 2007 6 (1) 334-345; DOI:10.1158/1535-7163.MCT-06-0404

  • Research Articles: Therapeutics, Targets, and Development
    Modulation of topoisomerase IIα expression by a DNA sequence-specific polyamide
    Daniel Hochhauser, Minal Kotecha, Caroline O'Hare, Peter J. Morris, Janet M. Hartley, Zarmeen Taherbhai, Dorothy Harris, Claudia Forni, Roberto Mantovani, Moses Lee and John A. Hartley
    Mol Cancer Ther January 1 2007 6 (1) 346-354; DOI:10.1158/1535-7163.MCT-06-0503

  • Research Articles: Therapeutics, Targets, and Development
    Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair
    Joshua L. Fischer, Elaine M. Mihelc, Karen E. Pollok and Martin L. Smith
    Mol Cancer Ther January 1 2007 6 (1) 355-361; DOI:10.1158/1535-7163.MCT-06-0472

  • Research Articles: Therapeutics, Targets, and Development
    Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3β activity in human breast cancer cells
    Vanessa Soto-Cerrato, Francesc Viñals, James R. Lambert, Julie A. Kelly and Ricardo Pérez-Tomás
    Mol Cancer Ther January 1 2007 6 (1) 362-369; DOI:10.1158/1535-7163.MCT-06-0266

  • Research Articles: Therapeutics, Targets, and Development
    The role of autophagy in the death of L1210 leukemia cells initiated by the new antitumor agents, XK469 and SH80
    David Kessel, John J. Reiners Jr., Stuart T. Hazeldine, Lisa Polin and Jerome P. Horwitz
    Mol Cancer Ther January 1 2007 6 (1) 370-379; DOI:10.1158/1535-7163.MCT-05-0386

  • Research Articles: Therapeutics, Targets, and Development
    A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas
    Farzan Siddiqui, Chuan-Yuan Li, Susan M. LaRue, Jean M. Poulson, Paul R. Avery, Amy F. Pruitt, Xiuwu Zhang, Robert L. Ullrich, Donald E. Thrall, Mark W. Dewhirst and Marlene L. Hauck
    Mol Cancer Ther January 1 2007 6 (1) 380-389; DOI:10.1158/1535-7163.MCT-06-0342

Back to top
PreviousNext
Molecular Cancer Therapeutics: 6 (1)
January 2007
Volume 6, Issue 1
  • Table of Contents
  • About the Cover

Sign up for alerts

Issue Highlights

  • Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase

Jump to

  • Drug Development Series: Review
  • Reviews
  • Research Articles: Therapeutics, Targets, and Development
Advertisement
  • Most Cited
  • Most Read
Loading
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • Truncated BRCA2 Contributes to PARPi Resistance
  • ERPAS to Predict Response to Endocrine Therapy
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Sialoglycan mAb for Cancer Immunotherapy
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement